The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

BIIB080 is an investigational antisense oligonucleotide therapy that targets microtubule-associated protein tau mRNA preventing the production of the disease-causing protein.

Ultragenyx Pharmaceuticals RARE announced that the FDA has granted the Breakthrough Therapy designation to its ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...

Seizures initially occurred at a rate of 20 to 25 per hour and declined to five to seven per hour following repeated intrathecal dosing with elsunersen, an antisense oligonucleotide therapy.

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular ...

Cure Rare Disease launched its SCA3 program in 2021 to develop an antisense oligonucleotide (ASO) therapy, with initial funding support provided by Gregory Klassen, a patient living with SCA3.

Trace Neuroscience, founded in January, has launched with $101 million raised in a series A financing round to advance its antisense oligonucleotide therapy (ASO) treatment for amyotrophic lateral ...

According to the latest research by InsightAce Analytic, the Global Oligonucleotide Therapy Market is valued at US$5.21 Bn in 2023, and it is expected to reach US$ 19.92 Bn by 2031, with a CAGR of ...

BIIB080 is an investigational antisense oligonucleotide therapy that targets microtubule-associated protein tau mRNA preventing the production of the disease-causing protein.